COMPANY

Elion Therapeutics

Profile checked Oct 10, 2026

Keywords: Invasive Mould Infection EL219

Timeline

Feb 13, 2026 Trial start 2: Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy source ↗

2026-12 (ESTIMATED) · 2 · Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy · NCT07215273

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07215273	Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy	2	Recruiting	Feb 13, 2026	2026-12 (estimated)